HK Stock Market Move | HUTCHMED (00013) up more than 3%, will begin promoting HMPL-A251 for clinical development by the end of the year.

HUTCHMED (00013) rose more than 3%, rising 2.95% as of press time, to 24.46 Hong Kong dollars, with a turnover of 65.5225 million Hong Kong dollars. On the news front, according to HUTCHMED's official WeChat account, HUTCHMED shared its latest key research and business developments at an investor conference held on October 31, 2025. The event highlighted HUTCHMED's latest progress in advancing innovative cancer and immune disease treatments, including the introduction of its new generation Antibody-Drug Conjugate ("ATTC") platform, as well as the latest progress on late-stage pipeline candidates. It was reported that the first candidate drug on HUTCHMED's ATTC platform, HMPL-A251, is a PAM-HER2 ATTC, formed by linking a highly selective and potent PI3K/PIKK inhibitor as the payload to a humanized anti-HER2 IgG1 antibody through a cleavable linker. Its preclinical data was recently presented at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference. The company stated that it will begin clinical development of HMPL-A251 by the end of 2025. Initial studies will evaluate the performance of this candidate drug in multiple tumor types with different HER2 and PAM alteration statuses.